Loading…
Loading…
KNSA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for KNSA and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for KNSA and 80,000+ other tickers.
See exactly how KNSA's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for KNSA and 80,000+ other tickers.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin…
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday. The company traded as high as $83.78 and last traded at $83.17, with a volume of 1,235,582 shares traded. The stock had previously closed at $79.48. Wall Street Analyst Weigh In A number of brokerages
B. Riley Wealth Advisors Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,232 shares of the company's stock, valued at approximately $763,000. Other
Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ: KNSA - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Analyst Recommendations This is a summary
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target